4Gridelli C, Rossi A, Maione P, et al. Erlotinib in non- small-cell lung cancer [ J 1. Expert Opin Pharmacother, 2007, 8 (15) : 2579 - 2592.
5Kunimasa K, Yoshioka H, Iwasaku M, et al. Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity [ J ]. Intern Med,2012, 51 (4):431-434.
6Takeda M, Okamoto I, Fukuoka M, et al. Successful treatment with erlotinib after gefitinib-related severe hepato- toxicity [J]. J Clin Oncol, 2010, 28 (17) : e273 - e274.
7Kijima T, Shimizu T, Nonen S, et al. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxici- ty: difference in metabolism as a possible mechanism [ J]. J Clin Oncol, 2011,29 (19): e588 -e590.
8Melosky B. Supportive care treatments for toxicities of anti- egfr and other targeted agents [J]. Curr Oncol, 2012, 19 ( Suppl 1 ) : $59 - $63.
5NAVARRO V J, SENIOR J R. Drug-related hepatotoxicity[J]. N Engl J Med, 2006, 354 (7) : 731-739.
6DANAN G, BENICHOU C. Causality assessment of adverse reactions to drugs-Ⅰ . a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries[ J]. J Clin Epidemiol, 1993, 46 (11) : 1323-1330.
7BENICHOU C, DANAN G, FLAHAULT A. Causality assessment of adverse reactions to drugs-Ⅱ. an original model for validation of drug causality assessment methods: case reports with positive rechallenge [ J]. J Clin Epidemiol, 1993, 46 (11) : 1331-1336.
8Bjiomsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease[J]. Hepatology,2005,42(2) :481 -489.
9Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity [ J ]. Respirology ,2006,11 ( 6 ) :699 - 707.
10Sakurai A, Kurata A, Onishi Y, et al. Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump[J]. Expert Opin Drug Saf,2007,6( 1 ) :71 - 86.
1You Q,Guo H,Xu D.Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer[J].Drug Des Devel Ther,2015;9(5):5087-97.
2Hirai F.Role of anti-angiogenesis therapy for advanced non-small cell lung cancer-current status and future challenges[J].Gan To Kagaku Ryoho,2015;42(8):940-3.
3Normando SR,Cruz FM,Del Giglio A.Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer[J].Anticancer Drugs,2015;26(9):995-1003.
4Zhong A,Xiong X,Shi M,et al.The efficacy and safety of pemetrexedbased doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer:an updated meta-analysis[J].Drug Des Devel Ther,2015;9(18):3685-93.
